Pharmaceuticals

AbbVie (NYSE: ABBV) Posts Q1 Revenue of $15B, Raises Guidance

AbbVie reports Q1 2026 net revenues of $15 billion, up 12.4%, on Skyrizi and neuroscience gains, and raises its 2026 adjusted diluted EPS guidance range.

AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1

AstraZeneca reported Q1 2026 total revenue of $15.3bn, up 8% at constant exchange rates, as oncology and rare disease offset CVRM declines.

Market Insights on Iran's Political Dynamics and Future Prospects

Market insights reveal changing probabilities for Reza Pahlavi’s return to Iran and potential regime changes amid growing instability.

Impact of the Strait of Hormuz Closure on Global Markets

The closure of the Strait of Hormuz disrupts energy and pharmaceutical supplies, with minimal chance for a return to normal by April.

Putin's Meeting with Iranian Foreign Minister: Analyzing Market Impact and Strategic Importance

Putin's meeting with Iran's Foreign Minister cements their partnership without altering US-Iran talks, leaving investors with limited trading opportunities.

UN Warns of Medical Supply Shortages Amid Conflict in Iran

The UN alerts of medical supply shortages in Iran due to ongoing conflict, impacting market optimism and trade routes.

The Impact of the Iran War on Global Medicine Prices and Oil Markets

The Iran war is disrupting supply chains, leading to rising global medicine prices and affecting oil market stability.

Iran's Use of Foreign Militias Signals Strain on Regime Stability

Iran's regime's dependency on foreign militias indicates a decrease in likely protests. Current market odds show 7.5% chance of regime change.

Impact of Trump's Medical Marijuana Reclassification on Investors

The Trump administration reclassifies medical marijuana to Schedule III, affecting research access and investor expectations.

Healthcare Workers in Tehran Anticipate Medicine Shortage Amid Rising Naval Tensions

Tehran healthcare workers fear a medicine shortage due to a naval blockade disrupting supply chains as tensions rise in the Strait of Hormuz.

Implications of the Trump Administration's Marijuana Reclassification

The Trump administration has reclassified FDA-approved marijuana, impacting the market outlook and trading dynamics around its use and potential.

Impact of the US Justice Department's Marijuana Rescheduling on Market Dynamics

The US Justice Department's reclassification of medical marijuana has shifted market dynamics, impacting investor sentiment and trading strategies.

Market Implications of Medical Marijuana Rescheduling to Schedule III

The Acting Attorney General rescheduled medical marijuana to Schedule III, affecting market odds and trading behavior. What does this mean for investors?

Exploring the Transformative Potential of GLP-1 Medicines and Their Impact on Public Health

GLP-1 medicines are set to exceed $100 billion in revenue, signaling a major revolution in public health and investment opportunities.

Project Prometheus and Its Role in AI Innovation

Jeff Bezos' Project Prometheus is raising $10 billion, aiming to revolutionize industries through physical AI systems and attract significant investments.